H.C. Wainwright maintains $11 target on Kamada stock

Fein’s reiteration of the Buy rating and $11 price target comes as he sees Kamada’s blend of steady revenue and potential for growth in its therapeutic pipeline as a compelling opportunity for GARP-focused investors. The special dividend and the company’s acquisition strategy further support the view that Kamada is well-positioned for continued growth. The company’s attractive PEG ratio of 0.42 suggests potential undervaluation relative to its growth prospects. For deeper insights into Kamada’s valuation and growth metrics, investors can access the comprehensive Pro Research Report available on InvestingPro, which includes detailed analysis of the company’s financial health and growth prospects. The company’s attractive PEG ratio of 0.42 suggests potential undervaluation relative to its growth prospects. For deeper insights into Kamada’s valuation and growth metrics, investors can access the comprehensive Pro Research Report available on InvestingPro, which includes detailed analysis of the company’s financial health and growth prospects.

Fein’s reiteration of the Buy rating and $11 price target comes as he sees Kamada’s blend of steady revenue and potential for growth in its therapeutic pipeline as a compelling opportunity for GARP-focused investors. The special dividend and the company’s acquisition strategy further support the view that Kamada is well-positioned for continued growth. The company’s attractive PEG ratio of 0.42 suggests potential undervaluation relative to its growth prospects. For deeper insights into Kamada’s valuation and growth metrics, investors can access the comprehensive Pro Research Report available on InvestingPro, which includes detailed analysis of the company’s financial health and growth prospects.

The company’s decision to issue a special dividend today was also discussed by Fein. He interpreted this move, along with management’s ongoing discussions about acquiring external commercial assets, as a sign that any future acquisitions would likely be modest in scale. This strategic approach is expected to prevent any significant deviation from the company’s established path, which Fein views as positive for investors.

Fein’s reiteration of the Buy rating and $11 price target comes as he sees Kamada’s blend of steady revenue and potential for growth in its therapeutic pipeline as a compelling opportunity for GARP-focused investors. The special dividend and the company’s acquisition strategy further support the view that Kamada is well-positioned for continued growth.

In other recent news, Kamada Ltd (NASDAQ:KMDA) reported its fourth-quarter 2024 earnings, showing an earnings per share (EPS) of $0.07, surpassing analysts’ expectations of $0.05. The company’s revenue for the quarter was $39.01 million, slightly below the anticipated $40.11 million. Kamada declared a special cash dividend of $0.20 per share, reflecting its strong financial performance and confidence in future growth. The company forecasts significant growth in 2025, with a revenue target of $178-182 million and plans to launch two additional biosimilar products. Kamada’s total revenue for 2024 reached $161 million, marking a 13% increase from the previous year, with net income rising to $14.5 million, a 75% increase from 2023. The company’s adjusted EBITDA was $34.1 million, up 42% year-over-year. Kamada’s strategic initiatives, including the expansion of its biosimilar portfolio and plasma collection centers, contributed to this growth. Additionally, the company is exploring mergers and acquisitions to support its growth strategy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.